Anticipated Highlights from AbbVie's Upcoming Financial Statement Release
AbbVie Inc. (ABBV), a North Chicago-based pharmaceutical company, is gearing up to announce its fiscal second-quarter earnings for 2025 on Thursday, Jul. 31. Despite a conservative forecast due to increased expenses, market consensus and analyst estimates indicate a robust performance.
The company has entered the obesity market with new drugs, and its focus on immunology, oncology, and other therapeutic areas continues to yield significant results. The success of its immunology medicines Skyrizi and Rinvoq, as well as strategic acquisitions such as Capstan Therapeutics and ImmunoGen, have contributed to ABBV's impressive outperformance.
AbbVie itself forecasted an adjusted EPS of $2.84 to $2.88 for Q2 2025, reflecting an impact from acquired IPR&D and milestones expenses estimated at $823 million. This guidance was a downward revision from prior estimates and below the consensus estimate at that time, which was around $3.18.
The consensus EPS forecast reported on Nasdaq remained steady at $3.24 for the quarter ending June 2025, while independent analysts noted expectations of an adjusted EPS figure near $3.22. Although the Earnings ESP was slightly negative (-3.61%), indicating some caution, AbbVie has a strong history of beating estimates.
Investors are watching closely for AbbVie’s performance on July 25, 2025, as any earnings beat could positively influence stock ratings and investor sentiment.
Looking ahead, analysts predict that AbbVie Inc.'s EPS will rise 14.5% year over year to $14.06 in fiscal 2026. Over the past 52 weeks, ABBV's stock has outperformed the S&P 500 Index's 13.4% gains, with shares up 15.5%.
The average analyst price target for ABBV is $208.88, indicating a potential upside of 10.4% from the current levels. Out of 27 analysts covering the stock, 14 advise a "Strong Buy" rating, two suggest a "Moderate Buy," and 11 give a "Hold." Analysts' consensus opinion on ABBV stock is moderately bullish, with a "Moderate Buy" rating overall.
For the full year of 2025, analysts expect AbbVie Inc. to report EPS of $12.28, a 21.3% increase from the $10.12 in fiscal 2024. AbbVie Inc. has a market cap of $334.3 billion.
[1] https://www.fool.com/investing/2023/04/26/abbvie-earnings-preview-q1-2023-expectations-and-wh/ [2] https://www.zacks.com/stock/news/3079152/abbvie-inc-abbv-q1-2023-earnings-preview [3] https://www.nasdaq.com/market-activity/stocks/abbv/earnings [4] https://www.nasdaq.com/articles/abbvie-inc-abbv-q1-2023-earnings-what-to-expect-from-the-pharmaceutical-giant-2023-04-26 [5] https://www.investorplace.com/2023/04/abbvie-inc-abbv-earnings-preview-q1-2023-what-to-expect-from-the-pharmaceutical-giant/
[1] Personal-finance enthusiasts may find an opportunity in investing in AbbVie Inc. (ABBV) on Thursday, Jul. 31, as the company's robust performance and the potential for beating analyst expectations could positively impact the stock.
[2] Given AbbVie's strong history of beating estimates, individuals interested in business and financial growth may want to consider adding ABBV to their personal-finance portfolios, as analysts predict a 14.5% year-over-year EPS increase to $14.06 in fiscal 2026.
